Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukaemia.
Cyclosporine was used to induce graft-versus-host disease (GVHD) in patients with acute myeloid leukaemia (AML) receiving autologous bone marrow transplantation (ABMT). Nine consecutive patients with AML in remission were conditioned with either busulphan and cyclophosphamide or melphalan and total body irradiation (TBI) followed by ABMT. Cyclosporine, 1 mg/kg daily from days 1-28 was administered intravenously in four patients and orally in five. Acute GVHD of the skin, confirmed by histological and immunological criteria occurred in three patients, 4-28 days after ABMT and lasted 8-18 days. Incidence and severity of GVHD were independent of cyclosporine levels. Three patients subsequently relapsed, of whom two had had evidence of GVHD. All of these patients were in second remission at time of graft, and therefore poor risk. The potential of cyclosporine to induce GVHD in the AML autograft setting is demonstrated, although the significance of this observation in terms of an antileukaemia effect needs clarification.
Talbot
D C
DC
Leukaemia Unit, Royal Marsden Hospital, Sutton, UK.
Powles
R L
RL
Sloane
J P
JP
Rose
J
J
Treleaven
J
J
Aboud
H
H
Helenglass
G
G
Parikh
P
P
Smith
C
C
Rowley
M
M
D000328:Adult; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003524:Cyclosporins / Q000494:pharmacology*; D005260:Female; D006086:Graft vs Host Disease / Q000139:chemically induced*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000276:immunology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D014182:Transplantation, Autologous
D003524:Cyclosporins